Anti-diabetic Compounds & Obesity Peptides

New approaches for Diabetes & Obesity Research

Diabetes & obesity have attained epidemic global levels. They are significant contributing factors to the worldwide spread of further chronic diseases, including coronary artery disease, myocardial infarction, hypertension, dyslipidemia and various other complicated disorders.

Clinically, diabetes mellitus is identified by a pronounced growth in blood glucose levels and is linked to mild hyperlipidemia. Moreover, obesity is the accretion of body fat to such an extent that it causes lowered life expectancy and other significant health issues, including type 2 diabetes.

A considerable amount of research has been undertaken in the development of preventive and therapeutic approaches towards diabetes and obesity. Some contemporary research strategies comprise receptors targeting, islet cell transplantation, gene expression profiling, glucagon-like peptide-1, dipeptidyl peptidase IV inhibitors, insulin therapy, modulators of peroxisome proliferator-activated receptors (PPAR), glucagon receptor antagonists, insulin analogues, ghrelin, peptide YY and combination therapies. BioVision is popular for providing broad variety of assay kits, high level anti-diabetic compounds and obesity peptides for both in vitro & in vivo research.

BioVision Incorporated

BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area.

BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jun 20, 2019 at 12:34 PM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BioVision Incorporated. (2019, June 20). Anti-diabetic Compounds & Obesity Peptides. News-Medical. Retrieved on January 18, 2020 from https://www.news-medical.net/whitepaper/20190527/Anti-diabetic-Compounds-Obesity-Peptides.aspx.

  • MLA

    BioVision Incorporated. "Anti-diabetic Compounds & Obesity Peptides". News-Medical. 18 January 2020. <https://www.news-medical.net/whitepaper/20190527/Anti-diabetic-Compounds-Obesity-Peptides.aspx>.

  • Chicago

    BioVision Incorporated. "Anti-diabetic Compounds & Obesity Peptides". News-Medical. https://www.news-medical.net/whitepaper/20190527/Anti-diabetic-Compounds-Obesity-Peptides.aspx. (accessed January 18, 2020).

  • Harvard

    BioVision Incorporated. 2019. Anti-diabetic Compounds & Obesity Peptides. News-Medical, viewed 18 January 2020, https://www.news-medical.net/whitepaper/20190527/Anti-diabetic-Compounds-Obesity-Peptides.aspx.

Other White Papers by this Supplier